Bausch Health Companies Inc

Bausch Health Companies Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.42
  • Today's Change-0.135 / -1.79%
  • Shares traded1.65m
  • 1 Year change-69.54%
  • Beta0.9317
Data delayed at least 15 minutes, as of Dec 06 2022 17:28 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Bausch Health Companies Inc. is a specialty pharmaceutical and medical device company. The Company develops, manufactures, and markets, primarily in the therapeutic areas of eye health, gastroenterology (GI), and dermatology, a range of branded, generic and branded generic pharmaceuticals, over the counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries. The Company operates through five segments: Bausch + Lomb, Salix, International, Solta Medical, and Diversified Products. The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical, and Ophthalmic Pharmaceuticals products. The Salix segment consists of sales in the United States of gastrointestinal (GI) products. The Solta Medical segment consists of global sales of Solta aesthetic medical devices.

  • Revenue in CAD (TTM)11.04bn
  • Net income in CAD345.14m
  • Incorporated2013
  • Employees19.60k
  • Location
    Bausch Health Companies Inc2150 Saint-Elzear Blvd WLAVAL H7L 4A8CanadaCAN
  • Phone+1 (514) 744-6792
  • Fax+1 (514) 744-6792
  • Websitehttps://www.bauschhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
ACADIA Pharmaceuticals Inc511.50m-217.34m2.47bn510.00--5.80--4.82-1.34-1.343.162.630.77491.028.79995,142.00-32.93-36.86-38.97-41.6597.9894.45-42.49-71.294.42--0.00--9.6094.6440.38---34.78--
Corcept Therapeutics Incorporated397.62m116.87m2.52bn238.0023.535.3221.396.340.99450.99453.394.400.71090.952714.221,670,689.0020.8931.2322.9034.9898.6898.2529.3938.318.41--
Amylyx Pharmaceuticals Inc345.00k-184.02m2.55bn205.00--15.65--7,397.65-3.28-3.280.00612.460.0022----1,682.93-118.00---139.35--50.14---53,337.68--5.26--0.00---56.15---107.97------
SAGE Therapeutics Inc6.46m-510.35m2.59bn471.00--1.88--400.55-8.63-8.630.109323.200.0038--0.303213,723.99-29.90-20.12-31.56-21.5188.29---7,895.27-96.50----0.00---99.43---175.55---23.51--
Myovant Sciences Ltd333.32m-189.59m2.60bn579.00------7.79-2.00-2.003.51-5.320.5735.7813.84575,687.40-32.59-79.01-58.93-134.7874.69---56.88-401.621.74-10.84----289.39--19.27--0.1444--
Immunocore Holdings PLC - ADR124.64m-67.53m2.63bn324.00--7.09--21.11-1.56-1.562.728.190.2638--7.44384,704.00-14.29---17.24--93.22---54.18--5.21-54.190.2008---11.93---77.51------
Insmed Incorporated242.18m-434.39m2.69bn613.00------11.13-3.63-3.632.03-0.24610.210.827710.37395,076.70-37.67-44.83-42.25-51.0977.15---179.36-300.504.11-22.931.04--14.63---47.80--11.66--
Ginkgo Bioworks Holdings Inc527.92m-3.53bn2.75bn641.00--2.07--5.22-2.23-2.230.33040.87050.262651.556.34823,580.30-175.92---189.42--54.43---670.03--11.67-34.410.0399--309.40---1,345.43------
Bausch Health Companies Inc8.13bn254.00m2.76bn19.60k10.82--1.650.3390.6980.69822.47-1.450.29262.214.69414,642.800.9721-3.501.19-4.0771.2371.803.32-14.220.77110.95570.98--5.07-2.71-69.29---0.556--
Ultragenyx Pharmaceutical Inc343.37m-678.05m2.79bn1.12k--5.95--8.13-9.74-9.744.946.690.22131.4312.14306,854.30-43.70-28.67-49.49-32.1792.2895.86-197.47-188.734.36-18.980.00--29.66383.49-143.36--48.31--
Tilray Inc613.56m-508.63m2.86bn1.80k--0.6215--4.66-0.9701-0.97011.207.530.1062.016.28340,866.70-8.04---8.72--18.66---75.84--2.44--0.1232--22.47---29.77------
Prothena Corporation PLC5.15m-156.48m2.92bn82.00--7.15--566.83-3.34-3.340.11028.450.0087----62,853.66-26.36-18.89-28.26-20.06-----3,036.03-186.86----0.00--23,414.30185.63160.26---48.99--
IVERIC bio Inc0.00-159.18m2.93bn148.00--10.17-----1.34-1.340.002.150.00----0.00-54.93-8.03-59.56-9.03-------38.40----0.00-------35.45---8.79--
PTC Therapeutics, Inc.696.62m-531.39m2.96bn1.25k------4.24-7.46-7.469.78-3.160.38882.836.30556,403.40-29.66-22.04-39.39-26.2893.8195.21-76.28-84.291.20-2.981.27--41.4545.46-19.57--73.86--
Blueprint Medicines Corp272.28m-717.56m3.00bn602.00--4.69--11.03-12.10-12.104.5810.710.18550.791710.55550,052.50-48.88-23.88-54.35-26.4492.47---263.54-96.066.79-99.640.1777---77.3145.34-305.20--5.59--
Data as of Dec 06 2022. Currency figures normalised to Bausch Health Companies Inc's reporting currency: US Dollar USD

Institutional shareholders

41.71%Per cent of shares held by top holders
HolderShares% Held
Icahn Associates Holding LLCas of 30 Sep 202234.72m9.60%
Paulson & Co., Inc.as of 30 Sep 202226.44m7.31%
Nomura Securities Co., Ltd. (Private Banking)as of 30 Sep 202216.49m4.56%
GoldenTree Asset Management LPas of 30 Sep 202216.49m4.56%
Franklin Advisers, Inc.as of 30 Sep 202215.79m4.36%
Laurion Capital Management LPas of 30 Sep 202210.81m2.99%
D. E. Shaw & Co. LPas of 30 Sep 20228.23m2.28%
Natixis Investment Managers International SAas of 30 Sep 20228.00m2.21%
The Vanguard Group, Inc.as of 30 Sep 20227.93m2.19%
MFN Partners Management LPas of 30 Sep 20226.00m1.66%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.